Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples